nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

26.08.2019 | Retinal Disorders

Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study

verfasst von: Alejandro Fonollosa, Javier Zarranz-Ventura, Alicia Valverde, Erika Becerra, Carolina Bernal-Morales, Salvador Pastor-Idoate, Miguel Angel Zapata

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to evaluate the predictive capacity of the baseline hyperreflective dots (HRDs) on the functional and anatomical response in patients with diabetic macular edema (DME). Additionally, we assessed the impact of the intravitreal dexamethasone (DEX) implant on the functional and anatomic outcomes.

Methods

Retrospective, multicenter study. The number of HRDs was graded in four different stages: [A] none HRDs; [B] few, 1–10 HRDs; [C] moderate, 11–20 HRDs; and [D] many, ≥ 21 HRDs. For statistical purposes, groups A and B were combined [scarce HRDs (S-HRDs)] and group D was renamed as [abundant HRDs (A-HRDs)]. The primary endpoints were the mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT) according to baseline HRD stage.

Results

One hundred eyes from one hundred patients were included in the study. Mean BCVA significantly improved from 52.9 (50.0 to 55.8) letters ETDRS at baseline to 57.2 (54.0 to 60.4) letters at month 6, p = 0.0039. There were no significant differences between the S-HRDs and A-HRD study groups in BCVA. As compared to baseline, CMT reduction was 106.3 (59.8 to 152.7) μm and 94.2 (34.7 to 153.7) μm in S-HRDs and A-HRD groups, respectively (p < 0.0001 each, respectively). Twenty-three (65.7%) and 18 (62.1%) eyes achieved a CMT reduction ≥ 10% in the S-HRD and A-HRD groups, respectively, p = 0.7640. DEX implant significantly reduced the presence of outer nuclear layer (ONL) disruptions (p = 0.0010).

Conclusions

The number of HRDs did not influence either functional or anatomic outcomes. DEX implant significantly decreases the number of eyes with ONL disruptions, which might improve retinal integrity.

Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4–14. https://doi.org/10.1016/j.diabres.2009.10.007 CrossRefPubMed

Pascolini D, Mariotti SP (2012) Global estimates of visual impairment: 2010. Br J Ophthalmol 96(5):614–618. https://doi.org/10.1136/bjophthalmol-2011-300539 CrossRefPubMed

Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ (2006) Impact of recentincrease in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 29(9):2114–2116CrossRefPubMed

Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J (2012) Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 57(4):347–370. https://doi.org/10.1016/j.survophthal.2012.01.004 CrossRefPubMed

Stewart MW, Flynn HW Jr, Schwartz SG, Scott IU (2016) Extended duration strategiesfor the pharmacologic treatment of diabetic retinopathy: current status and future prospects. Expert Opin Drug Deliv 13(9):1277–1287. https://doi.org/10.1080/17425247.2016.1198771 CrossRefPubMed

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS et al (2017) Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 237(4):185–222. https://doi.org/10.1159/000458539 CrossRefPubMed

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, RISE and RIDE Research Group et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomizedtrials: RISE and RIDE. Ophthalmology 119(4):789–801. https://doi.org/10.1016/j.ophtha.2011.12.039 CrossRefPubMed

Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J et al (2014) A randomized clinical trial of intravitrealbevacizumab versus intravitreal dexamethasone for diabetic macular edema: theBEVORDEX study. Ophthalmology 121(12):2473–2481. https://doi.org/10.1016/j.ophtha.2014.07.002 CrossRefPubMed

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Ozurdex MEAD Study Group et al (2014) Three-year, randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024 CrossRefPubMed

10.

Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M (2015) Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema. Ophthalmologica. 233(3–4):176–185. https://doi.org/10.1159/000371770 CrossRefPubMed

11.

Guigou S, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, Rouhette H, Rebollo O, Matonti F (2015) Efficacy and safety of intravitreal dexamethasone implantin patients with diabetic macular edema. Ophthalmologica 233(3–4):169–175. https://doi.org/10.1159/000381356 CrossRefPubMed

12.

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203. https://doi.org/10.1056/NEJMoa1414264 CrossRef

13.

Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ et al (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 172:72–79. https://doi.org/10.1016/j.ajo.2016.09.012. CrossRefPubMed

14.

Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK et al (2019) Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the international retina group real-life 24-month multicenter study. The IRGREL-DEXStudy. Retina 39(1):44–51. https://doi.org/10.1097/IAE.0000000000002196 CrossRefPubMed

15.

Nagpal M, Mehrotra N, Juneja R, Jain H (2018) Dexamethasone implant (0.7 mg) inIndian patients with macular edema: real-life scenario. Taiwan J Ophthalmol 8(3):141–148. https://doi.org/10.4103/tjo.tjo_62_17 CrossRefPubMedPubMedCentral

16.

Liu MM, Wolfson Y, Bressler SB, Do DV, Ying HS, Bressler NM (2014) Comparison oftime- and spectral-domain optical coherence tomography in management of diabetic macular edema. Invest Ophthalmol Vis Sci 55(3):1370–1377. https://doi.org/10.1167/iovs.13-13049 CrossRefPubMedPubMedCentral

17.

Dodo Y, Murakami T, Uji A, Yoshitake S, Yoshimura N (2015) Disorganized retinallamellar structures in nonperfused areas of diabetic retinopathy. Invest Ophthalmol Vis Sci 56(3):2012–2020. https://doi.org/10.1167/iovs.14-15924 CrossRefPubMed

18.

De Benedetto U, Sacconi R, Pierro L, Lattanzio R, Bandello F (2015) Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina 35(3):449–453. https://doi.org/10.1097/IAE.0000000000000336 CrossRefPubMed

19.

Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U (2012) Behavior ofSD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci 53(9):5814–5818. https://doi.org/10.1167/iovs.12-9950 CrossRefPubMed

20.

Framme C, Wolf S, Wolf-Schnurrbusch U (2010) Small dense particles in the retina observable by spectral-domain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 51(11):5965–5969. https://doi.org/10.1167/iovs.10-5779 CrossRefPubMed

21.

Vujosevic S, Torresin T, Bini S, Convento E, Pilotto E, Parrozzani R, Midena E (2017) Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol 95(5):464–471. https://doi.org/10.1111/aos.13294 CrossRefPubMed

22.

Chatziralli IP, Sergentanis TN, Sivaprasad S (2016) Hyperreflective foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina 36(12):2319–2328CrossRefPubMed

23.

Hwang HS, Chae JB, Kim JY, Kim DY (2017) Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment. Invest Ophthalmol Vis Sci 58(13):5958–5967. https://doi.org/10.1167/iovs.17-22725 CrossRefPubMed

24.

Schreur V, Altay L, van Asten F, Groenewoud JMM, Fauser S, Klevering BJ, Hoyng CB, de Jong EK (2018) Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS One 13(10):e0206482. https://doi.org/10.1371/journal.pone.0206482 CrossRefPubMedPubMedCentral

25.

Gardner TW, Antonetti DA (2008) Novel potential mechanisms for diabetic macularedema: leveraging new investigational approaches. Curr Diab Rep 8(4):263–269CrossRefPubMed

26.

Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30(5):343–358. https://doi.org/10.1016/j.preteyeres.2011.05.002 CrossRefPubMedPubMedCentral

27.

Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R (2016) Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016:2156273CrossRefPubMedPubMedCentral

28.

Pareja-Ríos A, Ruiz-de la Fuente-Rodríguez P, Bonaque-González S, López-Gálvez M, Lozano-López V, Romero-Aroca P (2018) Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol 11(1):77–82. https://doi.org/10.18240/ijo.2018.01.14 CrossRefPubMedPubMedCentral

29.

Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M et al (2003) (2003); Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 110(9):1677–1682CrossRefPubMed

30.

Otani T, Kishi S, Maruyama Y (1999) Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 127(6):688–693CrossRefPubMed

31.

Kang JW, Chung H, Chan Kim H (2016) Correlation of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema. Retina 36(9):1630–1639. https://doi.org/10.1097/IAE.0000000000000995 CrossRefPubMed

32.

Uji A, Murakami T, Nishijima K, Akagi T, Horii T, Arakawa N, Muraoka Y, Ellabban AA, Yoshimura N (2012) Association between hyperreflective foci in the outerretina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol 153(4):710–7, 717.e1. https://doi.org/10.1016/j.ajo.2011.08.041 CrossRefPubMed

33.

Vujosevic S, Berton M, Bini S, Casciano M, Cavarzeran F, Midena E (2016) Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema. Retina 36(7):1298–1308. https://doi.org/10.1097/IAE.0000000000000912 CrossRefPubMed

34.

Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C, Diabetic Retinopathy Research Group Vienna (2009) Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 116(5):914–920. https://doi.org/10.1016/j.ophtha.2008.12.039 CrossRefPubMed

35.

Lee H, Jang H, Choi YA, Kim HC, Chung H (2018) Association between soluble CD14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 59(2):715–721. https://doi.org/10.1167/iovs.17-23042 CrossRefPubMed

36.

Sala-Puigdollers A, Figueras-Roca M, Hereu M, Hernández T, Morató M, Adán A, Zarranz-Ventura J (2018) Repeatability and reproducibility of retinal and choroidal thickness measurements in diabetic macular edema using swept-source optical coherence tomography. PLoS One 13(7):e0200819CrossRefPubMedPubMedCentral

Titel: Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study
verfasst von: Alejandro Fonollosa
Javier Zarranz-Ventura
Alicia Valverde
Erika Becerra
Carolina Bernal-Morales
Salvador Pastor-Idoate
Miguel Angel Zapata
Publikationsdatum: 26.08.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2019
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-019-04446-4

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Changes of choroidal structure and circulation after water drinking test in normal eyes

Smartphone-based fundus photography for screening of plus-disease retinopathy of prematurity

Reliability of periocular anthropometry using three-dimensional digital stereophotogrammetry

Factors associated with macular complications in highly myopic eyes with dome-shaped macular configuration

Ocular manifestations in patients with Stevens–Johnson syndrome in Malawi—review of the literature illustrated by clinical cases

Ethnicity and association with ocular, systemic manifestations and prognosis in 194 patients with sarcoid uveitis

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde